Clinical trials: Hematopoietic
- Condition Hematopoietic
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hematopoietic Stem Cell Mobilization
Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors
Data collection on the safety and efficacy of Zarzio® / Filgrastim HEXAL® in adult healthy unrelated stem cell donors undergoing peripheral blood progenitor cell mobilization.
- Trial name
- SMART (NCT01766934)
- Where
- 2 sites in Germany
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Sandoz
Hematopoietic Syndrome Due to Acute Radiation Syndrome
Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure
This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of HemaMax in healthy male and female volunteers.
- Trial name
- NCT01742221
- Testing
- HemaMax
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Neumedicines Inc.
Hematopoietic Syndrome Due to Acute Radiation Syndrome
Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome
The purpose of this study is to determine whether HemaMax is safe and well tolerated to support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation…
- Trial name
- NCT02343133
- Testing
- HemaMax
- Where
- 4 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Neumedicines Inc.
Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)
A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers
The purpose of this study is to determine whether BL-8040 is safe, tolerable and effective in the mobilization of Hematopoietic Stem Cells (HSC) in healthy volunteers
- Trial name
- NCT02073019
- Testing
- BL-8040
- Where
- Israel
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- BioLineRx, Ltd.
Hematopoietic Stem Cell Transplantation
NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers
This is the second clinical study of NOX-A12. This study intends to provide information on the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of repeated intravenous doses of NOX-A12 (2.0 and 4.0 mg/kg/d)…
- Trial name
- SNOXA12C101 (NCT01194934)
- Testing
- NOX-A12, Filgrastim, NOX-A12 in combination with Filgrastim
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- TME Pharma AG